SAN FRANCISCO--(BUSINESS WIRE)-- #aihealthcare--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a proposed collaboration with Guardant Health, Inc...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended Decembe...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company's Shield™ mul...

Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healt...

PALO ALTO, Calif. & TAMPA, Fla.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare t...

NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approva...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating...

Biotechnology stock Guardant Health (GH) is trading at 15-month highs today, last seen up 7% at $38.28. Shares have added 107.7% over the last nine months, and now stand nearly 42% higher in 2024.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board o...

The rock star money manager is starting to roll with the rallying market.

Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wa...

Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago.

Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key ...

There's nothing like free publicity to help goose the sales of a relatively new product.

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shiel...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective imme...